Affiliations of authors: P. Vahteristo, H. Nevanlinna, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland; K. Syrjäkoski, T. Kainu, Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University, and Tampere University Hospital, Finland; H. Eerola, Department of Obstetrics and Gynecology and Department of Oncology, Helsinki University Central Hospital; K. Holli, Department of Oncology, Tampere University Hospital; C. Blomqvist, Department of Oncology, Helsinki University Central Hospital, and Department of Oncology, Uppsala University Hospital, Sweden; O.-P. Kallioniemi, Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University, and Tampere University Hospital, and Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
Correspondence to: Heli Nevanlinna, Ph.D., Department of Obstetrics and Gynecology, P.O. Box 140, Haartmaninkatu 2, FIN-00029 Helsinki University Central Hospital, Helsinki, Finland (e-mail: Heli.Nevanlinna{at}hus.fi).
In our recent survey of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients (1), 15 of the 19 mutation carriers identified belonged to a group defined by three simple criteria (i.e., family history of ovarian cancer, index case patient diagnosed with breast cancer at 40 years, or two or more relatives diagnosed with breast cancer). However, better predictive factors for germline mutations are required. Here, we evaluate the possibility raised by Chappuis et al. that immunohistologic features of the tumor tissues could help in identifying patients for mutation testing.
Of the 1035 patients (1036 tumors), the histologic type was available in 998 (96.3%) tumors, the World Health Organization histologic grade (of 741 ductal carcinomas) was available in 706 (95.3%) tumors, the estrogen receptor (ER) status was available in 937 (90.5%) tumors, and the progesterone receptor (PR) status was available in 935 (90.3%) tumors. Table 1 compares the distribution of these four parameters in tumors from BRCA1 mutation carriers ("BRCA1") and BRCA2 mutation carriers ("BRCA2") and in noncarriers ("control").
|
BRCA2 tumors had a similar distribution of histologic subtypes as the controls. An association between BRCA2 status and tumor grade was observed, attributable to the absence of grade 1 tumors in the BRCA2 carriers. Loss of PR tended to be more common in the BRCA2 tumors than in the controls. ER positivity among the BRCA2 tumors was similar to that among the controls. We also determined the frequency of ER-positive lobular carcinomas among BRCA2 carriers, as suggested by Chappuis et al. Two such tumors (15.4%) were found among 13 BRCA2 tumors, a prevalence similar to that of control cancers (130 [14.4%] of 903 controls).
In our study, the cases came from a prospective mutation screening among unselected, newly diagnosed breast cancers, providing an unbiased, population-based tumor material. Our study was based on histology reports obtained in the context of clinical pathologic diagnosis, which reflects the kind of information available to a physician who needs to decide whether germline BRCA1 and BRCA2 mutation testing is appropriate for a particular patient. In retrospective reviews by expert pathologists, specific histologic features have been linked with BRCA1 and BRCA2 tumors (4). If such features were to be used in defining putative mutation carriers, they should be routinely included in pathology reports, and the reproducibility of defining such features should be assessed.
Although differences in histologic and biologic features exist between BRCA1 tumors and to some extent between BRCA2 tumors and sporadic tumors (25), it remains to be determined whether such differences translate to better criteria for defining putative mutation carriers. Because of the interrelationships of the predictive features, large studies are required to test their independent value in the context of germline mutation screening. We expect that improved immunohistologic or molecular classifiers for both BRCA1 and BRCA2 tumors will arise from surveys of genetic alterations (6) and global gene expression changes (7) in hereditary breast cancers.
NOTES
P. Vahteristo, K. Syrjäkoski, and H. Eerola contributed equally to this work.
Supported by the Academy of Finland, The Sigrid Juselius Foundation, The Finnish Cancer Society, Clinical Research Fund of Helsinki University Central Hospital, Research Fund of Tampere University Hospital, and Pirkanmaa Cancer Society.
We thank Dr. Päivi Heikkilä for critical reading of the manuscript.
REFERENCES
1
Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, et al. A population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:152931.
2 Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:150510[Medline]
3 Loman N, Johansson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:3109.[Medline]
4
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:113845.
5 Eisinger F, Nogues C, Guinebretiere JM, Peyrat JP, Bardou VJ, Noguchi T, et al. Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 1999;84:2637.[Medline]
6 Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:12227.[Abstract]
7 Hedenfalk IA, Duggan DJ, Chen Y, Bittner M, Borg A, Trent JM. Microarray analysis discriminates BRCA2 mutation-positive breast cancer biopsies from BRCA1 mutation-positive and sporadic breast tumors [abstract]. Am J Hum Genet 1999;65(suppl): A10.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |